Endocannabinoid Deficiency Syndrome and the Impact of Cannabis

Endocannabinoid Deficiency Syndrome and the Impact of Cannabis

The primary mode of action of cannabis within the body is through its interaction with

the endocannabinoid system (ECS). The botanical specimen harbors over a hundred

cannabinoids, including THC (Tetrahydrocannabinol) and CBD (Cannabidiol), each with distinct

physiological impacts (Stella et al., 2021). For instance, tetrahydrocannabinol (THC) can bind to

both CB1 and CB2 receptors, thereby imitating the actions of endocannabinoids. This

phenomenon results in psychotropic consequences, commonly referred to as the “high,” that are

linked to the utilization of marijuana.

In contrast to its counterparts, CBD does not exhibit direct binding affinity towards CB1

or CB2 receptors. The mechanism of action appears to inhibit the degradation of endogenous

cannabinoids within the body, leading to an augmentation of their bioavailability and efficacy

(Stella et al., 2021). Some empirical data indicates that CBD may exert its effects by modulating

non-cannabinoid receptors implicated in the modulation of pain and inflammation, among other

physiological processes